# First-Line Luspatercept in Transfusion-Dependent Lower-Risk Myelodysplastic Neoplasms

> **NCT07752121** · — · NOT_YET_RECRUITING · sponsor: **Bristol-Myers Squibb** · enrollment: 190 (estimated)

## Conditions studied

- Myelodysplastic Neoplasms

## Interventions

- **DRUG:** Luspatercept

## Key facts

- **NCT ID:** NCT07752121
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-08-24
- **Primary completion:** 2030-08-31
- **Final completion:** 2030-08-31
- **Target enrollment:** 190 (ESTIMATED)
- **Last updated:** 2026-08-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07752121

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07752121, "First-Line Luspatercept in Transfusion-Dependent Lower-Risk Myelodysplastic Neoplasms". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07752121. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*